Oblenio Bio Closes $62 Million Series B to Advance Tri-specific T-Cell Engager LBL-051 for Autoimmune Diseases into Clinical Development
· oblenio bio, inc.
Source Summary
Oblenio's Series B round was led by Pfizer Ventures, with participation from new investors Deep Track Capital, GV, and founding investor, Aditum Bio.
Advertisement